Cerus Corporation Announces Upcoming Financial Results
Cerus Corporation (Nasdaq: CERS) is set to announce its financial results for the third quarter of 2024. This pivotal moment, expected shortly after the stock market closes on a Wednesday, marks an important milestone for the company as it shares key insights from its recent performance.
Webcast and Conference Call Information
Details of the Webcast
Following the release of the financial results, Cerus will host a live conference call and webcast. The session is scheduled to begin at 4:30 P.M. ET, allowing management to discuss both financial results and the broader business outlook. Attendees can gain valuable insights directly from company leadership during this engaging presentation.
How to Participate
To partake in the live webcast, interested individuals should visit the Investor Relations section of Cerus' official website. Registration for the conference call is encouraged, and participants are advised to log in approximately ten minutes prior to the commencement of the event to ensure seamless access to the discussion.
Availability of Replay
In addition to the live session, a replay of the conference call will be accessible on Cerus’ website. This replay will become available roughly three hours post-call and will be accessible until November 20, 2024, allowing stakeholders to catch up on the proceedings at their convenience.
About Cerus Corporation
Cerus Corporation is committed to enhancing the safety of the global blood supply. Headquartered in Concord, California, the company aims to emerge as a leading global provider of blood product technologies. Their developments focus on providing pathogen-protected blood components that are essential for blood centers, hospitals, and patients needing safe blood.
Innovative Blood Safety Solutions
The company’s flagship product, the INTERCEPT Blood System, which is designed for both platelets and plasma, holds the notable distinction of being the only pathogen reduction system that has secured both CE mark and U.S. FDA approval. This is a testament to the system's quality and the company’s dedication to ensuring safe blood components are available globally.
Products Under Development
Cerus has also received approval for the INTERCEPT Blood System for Cryoprecipitation, enabling the production of pathogen-reduced Cryoprecipitated Fibrinogen Complex. This therapeutic solution is critical for treating bleeding, particularly in cases of massive hemorrhage related to fibrinogen deficiency. Additionally, the INTERCEPT red blood cell system remains in late-stage clinical development, signifying continual innovation and progress in blood safety.
Connecting with Cerus
For those looking to learn more about the advancements and offerings from Cerus Corporation, the company encourages visits to their official website, where additional product information and corporate updates are published regularly. Following Cerus on professional platforms such as LinkedIn also offers insights into the latest advancements and corporate news.
Frequently Asked Questions
When will Cerus Corporation release its Q3 2024 financial results?
Cerus Corporation will release its third quarter financial results after the market closes on the announced date.
How can I participate in the Cerus conference call?
Interested participants can register for the conference call via the Investor Relations section of the Cerus website, encouraged to join early.
Will there be a recording of the conference call available?
Yes, a replay of the conference call will be available on the Cerus website approximately three hours after the live session and will remain accessible until November 20, 2024.
What is the main focus of Cerus Corporation?
Cerus Corporation focuses on ensuring the safety of the blood supply by developing and supplying pathogen-protected blood technologies.
What products does Cerus offer to enhance blood safety?
Cerus offers the INTERCEPT Blood System for platelets and plasma, among others, designed specifically to provide pathogen reduction solutions.
